Novel drugs against non-small-cell lung cancer

Current Opinion in Oncology

Volumn 26, Issue 2, 2014, Pages 145-151

  Pirker, Robert ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Afatinib; Cetuximab; Crizotinib; Selumetinib; Targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 84894097464     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000056     Document Type: Review

References (46)

1. Pirker R, Popper H. New concepts in pulmonary oncology. Eur Respir Mon 2007; 39:1-22
2. Pirker R, Filipits M. Targeted therapies in lung cancer. Curr Pharm Des 2009; 15:188-206
3. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20:1S-13S
4. Pirker R, Minar W, Filipits M. Integrating epidermal growth factor receptortargeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer. Clin Lung Cancer 2008; 9:S109-5
5. Pirker R, Filipits M. Monoclonal antibodies against EGFR in non-small-cell lung cancer. Crit Rev Oncol Hematol 2011; 80:1-9
6. Kurai J, Chikumi H, Hashimoto K, et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007; 13:1552-1561
7. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009; 373:1525-1531
8. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: Results of the randomized multicenter phase III trial BMS099. J Clin Oncol 2010; 28:911-917
9. Pujol J-L, Pirker R, Lynch TJ, et al. Meta-Analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small-cell lung cancer. Lung Cancer 2013. [Epub ahead of print
10. Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: A subgroup analysis of data from the FLEX phase 3 study. Lancet Oncol 2011; 12:30-37
11. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al. Molecular biomarkers in nonsmall
12. Khambata-Ford S, Harbison CT, Hart LL, et al. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:918-927
13. Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 2012; 13:33-421
14. Hirsch FR, Herbst RS, Olsen C, et al. Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-smallcell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol 2008; 26:3351-3357
15. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. J Clin Oncol 2011; 29:3120-3125
16. Bradley J, Masters GA, Hu C, et al. An intergroup randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) chemoradiotherapy/ - cetuximab (cetux) for stage III non-small-cell lung cancer (NSCLC): Results on cetux from RTOG 0617. 15th World Conference on Lung Cancer; 27-30 October 2013; Sydney, Australia. Abstract PL03.05
17. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human antiepidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58:984-990
18. Schiller JH, von Pawel J, Schütt P, et al. Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV nonsmall-cell lung cancer. J Thorac Oncol 2010; 5:1977-1985
19. Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): A multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13:466-475
20. Pao W, Miller V, Zakowski M, et al.EGF receptor gene mutations are common in lung cancers from never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306-13311
21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139
22. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500
23. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for nonsmall-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-2388
24. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-128
25. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): A multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735-742
26. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239-246
27. Sequist LV, Yang JC-H, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3327-3334
28. WuYL, ZhouC, HuC-P, et al. LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M) advanced adenocarcinoma of the lung. J Clin Oncol 2013; 31 (suppl; abstract 8016
29. Yang JC-H, Hirsh V, Schuler M, et al. Symptom control and qualtiy of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31:3342-3350
30. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528-538
31. Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013; 31:4105-4114
32. McArthur GA. The coming of age of MEK. Lancet Oncol 2012; 13:744-745
33. Jänne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRASmutant advanced non-small-cell lung cancer: A randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013; 14:38-47
34. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693-1703
35. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-4253
36. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385-2394
37. Seto T, Kiura K, Nishio M, Nakagawa K, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): A single-Arm, open-label, phase 1-2 study. Lancet Oncol 2013; 14:590-598
38. Reck M, Kaiser R, Mellemgaard A, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after first-line chemotherapy: LUME Lung 1, a randomized, double-blind phase III trial. J Clin Oncol 2013; 31 (suppl; abstract LBA8011
39. Hanna NH, Kaiser R, Sullivan RN, et al. Lume-Lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31 (suppl; abstract 8034
40. Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: A randomized, controlled phase III trial. J Clin Oncol 2012; 30:3640-3647
41. Lara PN Jr, Douillard JY, Nakagawa K, et al. Randomized phase III placebocontrolled trial of carboplatin and paclitaxel with or without the vasculardisruptingagent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2965-2971
42. Sessa C, Lorusso P, Tolcher A, et al. Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors. Clin Cancer Res 2013; 19:4832-4842
43. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:1835-1842
44. Paz-Ares LG, Biesma B, Heigener D, et al. Phase III, randomized, doubleblind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. J Clin Oncol 2012; 30:3084-3092
45. Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/ paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30:2829-2836
46. Scagliotti GV, Krzakowski M, Szczesna A, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-smallcell lung cancer: A phase III trial. J Clin Oncol 2012; 30:2070-2078